MiMedx (MDXG) CEO Joseph Capper receives large stock and option awards

Rhea-AI Filing Summary

Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.

MiMedx Group, Inc. Chief Executive Officer Joseph H. Capper reported equity awards consisting of stock options and restricted stock granted on March 4, 2026. He was awarded 310,574 stock options and 371,094 shares of common stock at a price of $0.00 per share.

The restricted stock grant vests fully on the third anniversary of the grant date, subject to his continued employment under a Restricted Stock Unit Agreement. The stock options vest in four equal annual installments of 25% on each anniversary of the grant date, also subject to continued employment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capper Joseph H

(Last) (First) (Middle)

1775 WEST OAK COMMONS COURT NE

(Street)

MARIETTA GA 30062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		371,094(1)	A	$0	904,656(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$5.1	03/04/2026		A		310,574		(3)	03/03/2033	Common Stock	310,574	$0	4,087,938	D

Explanation of Responses:

1. Represents grant of restricted stock which vests fully on the third anniversary of the grant, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement.

2. Includes an aggregate of 4,032 shares acquired on July 31, 2025 and January 30, 2026 pursuant to the MiMedx Group, Inc. Employee Stock Purchase Plan.

3. The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment as specified in the Nonqualified Stock Option Agreement.

Remarks:

	/s/ William F. Hulse, as attorney-in-fact for Joseph Capper	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MiMedx (MDXG) report for CEO Joseph H. Capper?

MiMedx reported that CEO Joseph H. Capper received equity awards on March 4, 2026, including stock options and restricted stock. The awards were granted at $0.00 per share, reflecting compensation rather than open-market purchases, and are subject to future vesting based on continued employment conditions.

How many stock options were granted to the MiMedx (MDXG) CEO in this Form 4?

Joseph H. Capper was granted 310,574 stock options on March 4, 2026. These options vest 25% on each anniversary of the grant date, contingent on his continued employment under the Nonqualified Stock Option Agreement, aligning his long-term incentives with the company’s performance and tenure.

What restricted stock grant did MiMedx (MDXG) disclose for its CEO?

MiMedx disclosed a grant of 371,094 shares of common stock to CEO Joseph H. Capper at $0.00 per share. This restricted stock vests fully on the third anniversary of the March 4, 2026 grant date, provided he remains employed, as specified in the Restricted Stock Unit Agreement.

How do the MiMedx (MDXG) CEO’s new equity awards vest over time?

The CEO’s restricted stock fully vests on the third anniversary of the March 4, 2026 grant date, subject to continued employment. The stock options vest in four equal 25% installments on each anniversary of the same grant date, also requiring ongoing employment to realize the full award.

Were the MiMedx (MDXG) CEO’s equity awards open-market purchases or compensation grants?

The transactions were compensation grants, not market purchases. Both the 310,574 stock options and 371,094 restricted shares were awarded at $0.00 per share as part of his compensation package, with vesting tied to his continued employment rather than immediate cash investment in the stock.